Precision immunotherapy
for hard-to-treat diseases

At Imuno we develop the next generation of immunotherapies against an untapped universe of intracellular antigens that have been out-of-reach for conventional therapies.

We are redefining targeted immunotherapy by unlocking the vast potential of peptide-HLA (pHLA) antigens. Our proprietary Imuno TACTICS™ platform ensures unparalleled specificity and safety in TCRmimic (TCRm) antibody development, eliminating cross-reactivity while maximizing therapeutic potency. By combining structural epitope mapping with advanced paratope prediction, we engineer next-generation immunotherapies that precisely target intracellular disease antigens—opening new frontiers in oncology and autoimmune therapy.

Partner with us to bring safer, more effective immunotherapies to patients who need them most.